EDITORIAL SECTIONS
RESEARCH & DEVELOPMENT
Adopting the Power of AI to Drug Development Projects
A tremendous amount of documentation is created throughout the clinical trial lifecycle
CLINICAL TRIALS
Real-world Evidence
Hearing the diagnosis from the doctor that your child has spinal muscular atrophy SMA
MANUFACTURING
Just in Time Manufacturing Creating more sustainable supply chains
Drug development has transformed immeasurably over the past decade Even before the Covid pandemic and the conflict in Ukraine
Information Technology
Challenges and Advantages of Using Artificial Intelligence in Pharma
Many advanced largescale AI initiatives still need to be proved successful in Pharma
KNOWLEDGE BANK
Interviews
ExpreS2ion Biotechnologies
Vice President - Business Development
ExpreSion Biotechnologies protein expression system ExpreS is an important protein expression tool in the scientists tool box for protein expression The ExpreS platform has demonstrated in many instances its usefulness in RD with several ExpreSmade proteins having now been crystallized
Articles
Syringe-like Bacterial Nanomachine Emerges as Potential Therapeutics Delivery Device
CIS are syringelike cellpuncturing machines Bacteria deploy it for various natural functions including cellcell communications defence and in endosymbionts to interact with the hosts CIS translocate effectors molecules
Research Insights
Whole blood transcriptome biomarkers of unruptured intracranial aneurysm
The rupture of an intracranial aneurysm IA causes devastating subarachnoid hemorrhages yet most IAs remain undiscovered until they rupture Recently we found an IA RNA expression signature of circulating neutrophils
Case Studies
Variation In Adverse Drug Reactions Listed In Product Information For Antidepressants And Anticonvulsants, Between The Usa And Europe: A Comparison Review Of Paired Regulatory Documents
Abstract Objective To compare consistency of adverse drug reaction ADR data in publicly available product information documents for brand drugs between the USA and Europe and to assess the usefulness of information for prescribers and patients Design A comparison review of product info
Techno Trends
Israeli researchers at Technion find two proteins that can suppress cancer
A team of Israeli researchers at the Technion has discovered two proteins that can suppress cancer and control the cells growth and development The study was conducted in the laboratory of Prof Aaron Ciechanover an Israeli Nobelprize winner in chemistry and led by Dr Yelena KravtsovaIvantsiv The team included research students and physicians from the Rambam
White Papers
Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches
In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS
TOP ARTICLES
5 Proven Ways to Take PBM’s to the Future ‘Today’ with Conversational AI
Ravi Iyer is a visionary and innovative executive with diverse experience in leading and managing product delivery, client implementation, customer service, and operations with direct responsibility for multimillion-dollar budgets. He has extensive experience delivering across multiple disciplines, including Data Management, Data Governance, Cloud Architecture, Advanced Analytics, Master Data Management, Digital Products, and Digital Transformation. Excellent communicator who works collaboratively to deliver technology strategies and value added solutions that meet the needs of all business functions. Ravi is currently the technology executive and Senior Director at Elevance Health Inc.
Narasimha is result driven leader with vast experience in executing various PBM, Health care, Financial, and securities trading applications. Technical expertise in Big data, Cloud, Analytics, Mainframe, BPM, testing, and Data warehouse projects at esteemed organisations like Anthem, Tetrasoft, DST, HCL, Deutsche bank, and Atos Origin. He currently works as Solution Architect at Tetrasoft Inc. Narasimha has vast experience in Pre-sales, Project management, effective customer communication, Architect, Technical Lead, On-site coordinator, and business Analyst roles for various complex assignments across the globe.
Meet scientist Daria Donati
Daria’s work is ongoing. Her role at Cytiva involves identifying new and innovative technologies that can help in the development of therapeutics. This means building partnerships, improving manufacturing processes and, ultimately, getting life- saving drugs to the people who need them most.
Natural Polymers and Fibers in Drug Delivery
Dr. Meghraj V. Suryawanshi is an Associate Professor and Co-Founder of Sandip Institute of Pharmaceutical Sciences. He holds M.Pharm, MBA, PDCR, and Ph.D. degrees. With over 7 years of research experience and 4 years in teaching, his expertise lies in polymer science, novel drug delivery systems (NDDS), and intellectual property rights (IPR). Dr. Suryawanshi has authored more than 55 publications, 8 books, and holds several patents. He actively leads innovative pharmaceutical research with a strong focus on translational impact.
Akshata Yashwant Patne is a pharmaceutical nanotechnology expert with over 3 years of experience in clinical research, drug delivery, and AI-driven therapeutics. She has led nanoparticle-based studies, published peer-reviewed articles, and actively mentors students, combining science, innovation, and leadership across academia, research, and global scientific communities.
Generative AI and the New Era of Personalized Medicine
Uddalak Das, PhD scholar at IISc Bengaluru, specializes in drug discovery and cancer immunotherapeutics. With 20+ publications, a patent, and collaborations with institutes like NCBS, JNU, and inStem, he advances green healthcare solutions. He is a member of AACR and EACR among others and has received multiple national fellowships and research grants.
Nanotechnology as a Potential Therapeutic Strategy in Breast Cancer Management
Mr. Rahul Pal (Young Scientist), Ass. Prof. Department of Pharmacy, Jagannath University, Jaipur, holds B. Pharm, M. Pharm (Pharmaceutics), and PhD* at Chitkara University. He has authored 50+ publications, 8 textbooks, 12 edited book, secured 38 patents, 3 copyrights, received the Young Researcher Award (2025), and actively contributes as reviewer, editor, and speaker in national and international academic forums.
press releasesRead more...
CAS Connections brings trusted scientific data and AI to leading R&D platforms
CAS a division of the American Chemical Society specializing in scientific knowledge management today announced CAS Connections a new integration framework that embeds the CAS Content Collection
Teva Expands European biosimilars portfolio with launch of AHZANTIVE® (aflibercept) biosimilar to Eylea®
Teva Pharmaceutical Industries Ltd NYSE and TASE TEVA today announced the launch of AHZANTIVE aflibercept a biosimilar to Eylea in Europe further strengthening the Companys growing biosimilars portfolio and expanding
Amneal Announces U.S. FDA Approval of Romidepsin Injection Solution
Amneal Pharmaceuticals Inc Amneal or the Company Nasdaq AMRX today announced that the US Food and Drug Administration FDA has approved the Companys romidepsin injection solution mg mL
DaltonTx launches its drug discovery platform, Dalton, and announces Sygnature Discovery collaboration
DaltonTx the intelligence backbone for modern drug discovery connecting AI human expertise and experimental data today announced the launch of Dalton its drug discovery platform
Iovance’s Amtagvi® (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia
Iovance Biotherapeutics Inc NASDAQ IOVA a commercial biotechnology company focused on innovating developing and delivering novel polyclonal tumor infiltrating lymphocyte TIL therapies for patients with cancer
Arcus Biosciences Announces Clinical Trial Collaboration and Supply Agreement to Evaluate Casdatifan in Combination with PD‑L1/VEGF‑A Bispecific Immunomodulator to Treat Kidney Cancer
Arcus Biosciences Inc NYSE RCUS a clinicalstage global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases
EventsRead more...
04 - 05
Jun 2026Pharmac South 2026
Chennai Trade Centre, Nandamba...
04 - 05
Jun 2026Global Bioprocessing Summit & Exhibition 2026
Berlin, Germany
09 - 11
Jun 20265th World ADC Summit South Korea
COEX Magok Lewest, 143 Magokju...
09 - 11
Jun 2026World TPD & Induced Proximity Summit South Korea
COEX Magok Lewest, 143 Magokju...
09 - 11
Jun 2026World Targeted Therapeutics Summit South Korea
COEX Magok Lewest, 143 Magokju...
09 - 10
Jun 2026ChemE Show 2026
George R. Brown Convention Cen...
10 - 11
Jun 2026Novel Ingredients for Infant Nutrition Summit
The Westin Washington Dulles A...
10 - 11
Jun 202617th Annual Clinical Trials Summit 2026
Mumbai, India
LATEST NEWSRead more...
Stipple Bio Signs Licensing Agreement with Lonza for Precision Oncology ADC Development
Stipple Bio has entered a multitarget licensing agreement with Lonza to support the development of nextgeneration antibodydrug conjugate ADC therapies for cancer treatment
Biogen’s Salanersen Granted FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy
Biogen announced that the US Food and Drug Administration FDA has granted Breakthrough Therapy Designation to salanersen for the treatment of spinal muscular atrophy SMA
Chai Discovery Signs Licensing Agreement with Pfizer to Advance AI-Driven Drug Discovery
Chai Discovery has entered into a licensing agreement with Pfizer to support the use of artificial intelligence in drug discovery and accelerate the development of new medicines
Alnylam and Inceptive Partner to Accelerate RNAi Drug Discovery Using AI
Alnylam Pharmaceuticals Inc and Inceptive Nucleics Inc have entered into a strategic collaboration aimed at accelerating the discovery and development of RNA interference RNAi therapeutics through the use of artificial intelligence
Massive Bio and Optellum Partner to Improve Clinical Trial Access for Early-Stage Lung Cancer Patients
Massive Bio and Optellum have entered into a collaboration aimed at improving access to clinical trials for patients with earlystage nonsmall cell lung cancer NSCLC The partnership combines Optellums artificial intelligence
Travere Therapeutics Signs Licensing Agreement with Everest Medicines for Civorebrutinib
Travere Therapeutics has entered into an exclusive licensing and collaboration agreement with Everest Medicines for the development and commercialisation of civorebrutinib EVER an investigational oral Brutons tyrosine kinase